

**TIANJIN ZHONG XIN PHARMACEUTICAL GROUP CORPORATION LIMITED**  
(Company Registration No. 91120000103100784F)  
(Incorporated in People's Republic of China)

---

**RESPONSE TO SGX QUERY ON ANNUAL REPORT FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2020**

---

Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) has received a query from the Singapore Exchange Securities Trading Limited (the “**SGX-ST**”) regarding the Company’s annual report for the financial year ended 31 December 2020 (“**FY2020**”) announced on 30 April 2021 (the “**FY2020 Annual Report**”). The Company’s response to the SGX-ST’s query is set out below:-

**SGX Query 1**

Listing Rule 210(5)(a) states that a director who has no prior experience as a director of an issuer listed on the Exchange must undergo training in the roles and responsibilities of a director of a listed issuer as prescribed by the Exchange. If the nominating committee is of the view that training is not required because the director has other relevant experience, the basis of its assessment must be disclosed.

Please disclose if the new directors appointed to the Board during the financial period under review have attended training as required by the Exchange and provide the dates of the training. If no trainings have been attended, please explain why.

**Company’s response:**

At the Company’s annual general meeting held on 5 June 2020, the shareholders of the Company approved the appointments of (i) Liew Yoke Pheng Joseph and (ii) Li Yan as directors of the Company.

As disclosed on pages 54 and 56 of the Company’s annual report for the financial year ended 31 December 2019 issued on 21 May 2020 (“**FY2019 Annual Report**”), and in the announcement on appointment of Liew Yoke Pheng Joseph made by the Company on 5 June 2020, Mr. Liew is the Executive Chairman and Chief Executive Officer of Hoe Leong Corporation Ltd. (listed on the Mainboard of the Singapore Exchange Securities Trading Limited (“**SGX-ST**”) and the Lead Independent Director and Chairman of the Audit Committee of Grand Venture Technology Limited (listed on the Catalist of the SGX-ST). As Mr. Liew has prior experience as a director of an issuer listed on the SGX-ST, Mr. Liew is not required to undergo the mandatory training as prescribed by the SGX-ST pursuant to Listing Rule 210(5)(a).

As disclosed on page 60 of the FY2019 Annual Report, and in the announcement on appointment of Li Yan made by the Company on 5 June 2020, the Company will arrange for Ms. Li to attend training on the roles and responsibilities of a director of a listed issuer as prescribed by the SGX-ST. However, due to the ongoing restrictions in connection with the Covid-19 pandemic, Ms. Li has not had the opportunity to attend the relevant training, and will endeavour to do so once it is expedient to do so.

**By order of the Board**

Jiao Yan  
Company Secretary  
11 May 2021